Panelists discuss how emerging nonsteroidal topical therapies, including ruxolitinib, roflumilast, and tapinarof, offer new treatment options for pediatric patients with atopic dermatitis, providing effective alternatives to traditional topical steroids with improved safety profiles, simplified dosing regimens, and better tolerability across different age groups from infants to adolescents.
Nada Elbuluk, MD; and Corey L. Hartman, MD, discuss how melasma and postinflammatory hyperpigmentation are chronic conditions requiring individualized combination therapies that include topical lightening agents (both hydroquinone and newer nonhydroquinone alternatives such as thiamidol), retinoids, rigorous sun protection, and procedural interventions, emphasizing the importance of treating underlying acne in postinflammatory hyperpigmentation cases and maintaining long-term regimens to prevent recurrence.
Raj Chovatiya, MD, PhD, MSCI; and Lawrence Eichenfield, MD, discuss how the OX40-OX40L pathway represents a promising new therapeutic target for atopic dermatitis that works upstream in the immune cascade to modulate T-cell activation and proliferation, potentially offering more durable responses and broader efficacy across the heterogeneous patient population compared with current cytokine-specific treatments.
An expert discusses the evolving role of oral antibiotics in acne treatment, highlighting clinical evidence, antimicrobial resistance concerns, and emerging alternatives tailored to patient needs.
Supported by an independent medical grant by Almirall.
Panelists discuss how recent advancements in nonsteroidal topical therapies—particularly roflumilast and tapinarof—are transforming psoriasis management by offering safe, effective, and well-tolerated alternatives that improve adherence, address challenges across skin types and body areas (especially the scalp), reduce reliance on steroids and systemics, and support individualized, equitable, and long-term care.
Christopher Bunick, MD, PhD, and James Song, MD, discuss how IL-17 plays a key role in plaque psoriasis by driving inflammation. IL-17 inhibitors differ in targeting IL-17A, IL-17RA, or IL-17A/F, impacting efficacy and safety. These agents offer rapid skin clearance, improve patients’ quality of life, and require patient-specific selection based on clinical and real-world factors, including dosing, safety, and long-term data.
Susan Taylor, MD, FAAD, discusses the impact of the solar spectrum on skin health, focusing specifically on the impact of visible light and infrared radiation. She discusses the benefits and limitations of traditional sunscreen ingredients and addresses ways to specifically protect from visible light and infrared radiation. Additionally, she discusses the impact of free radical formation on skin health and how adding antioxidants to sunscreen might optimize skin protection. She also shares her perspective based on her clinical experience on how she talks to her patients about sun protection and how she chooses the right sunscreen for patients in her practice.
Panelists discuss how the shift from anti-aging to pre-aging skin care emphasizes early intervention, the role of micropeptides, and the importance of educating patients on maintaining healthy skin before visible signs of aging appear.
Panelists discuss how the role of cleansers in a balanced skin care routine is crucial for maintaining skin health, highlighting the importance of cleanser cadence, avoiding harshness, and exploring future innovations in cleanser formulations.
Panelists discuss how sunscreen plays a vital role in skin health and anti-aging, emphasizing the importance of UVA protection with zinc oxide and iron oxide for all skin tones, the moisturizing benefits of modern sunscreens, and the importance of patient education on the safety and use of mineral sunscreens.
Panelists discuss how advancements in topical PDE4 inhibitors, particularly roflumilast and crisaborole, are reshaping the management of atopic dermatitis by offering new nonsteroidal options with distinct mechanisms of action and safety profiles.
Karan Lal, DO, and Helen T Shin, MD, discuss the challenges, treatment options, research needs, and impact of pediatric plaque psoriasis, highlighting early diagnosis, the potential of PDE4 inhibitors, and the importance of addressing long-term safety and psychosocial effects.
Elizabeth Kiracofe, MD, and Jenny Murase, MD, explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.
Experts in dermatology provide a comprehensive year in review regarding the management of plaque psoriasis, highlighting key therapeutic approvals from 2023. The discussion will highlight pivotal clinical studies supporting these approvals and our discussion will then pivot to have a special focus on addressing the unique challenges faced by treating patients with skin of color and treatment access barriers.
Experts in dermatology delve into the unique characteristics of plaque psoriasis and its impact on patients' quality of life. They further explore how dermatological providers can optimize care by transitioning patients to more effective and innovative systemic options to manage this condition, ultimately advancing both patient outcomes and overall well-being.
Experts in dermatology explore how to facilitate and engage patients living with vitiligo in a constructive conversation about the use of topical therapy for this condition emphasizing the importance of appropriate follow-up and monitoring practices to ensure treatment success.
During this discussion, expert dermatologists focus on the role of nonsteroidal topicals in the treatment of plaque psoriasis. They highlight the safety and efficacy of these treatments and their role in the management of patients with plaque psoriasis.
Experts discuss their clinical experience using topical therapies to treat atopic dermatitis (AD), highlighting recent developments in the treatment landscape and prospective approaches for improved outcomes.
In this upcoming video program, Lauren Miller, PA-C will lead a conversation about the management of plaque psoriasis; focusing on data relating to emerging efficacy and safety outcomes highlighting key disease clearance endpoints related to the practical and clinical considerations of this condition.
Dermatology experts discuss non-steroidal, topical treatment options for patients with plaque psoriasis.
Experts in dermatology discuss prevalence, communication with patients, and exciting new treatments in vitiligo.
Psoriasis experts discuss updates with IL-17 inhibitors and how they have changed the treatment landscape for plaque psoriasis.
Psoriasis experts discuss updates with TNF inhibitors and how they have changed the treatment landscape for psoriatic disease.
Expert rheumatologist and dermatologist discuss biosimilars and impact of biosimilars on the field of rheumatology and dermatology.
Experts in dermatology discuss presentation and treatment of atopic dermatitis (AD) in patients with skin of color SOC). Through a discussion of patient cases, they present rationale for where and why they would use recently approved AD treatments in pediatric population.
Susan Taylor, MD, FAAD, provides an overview of sun-caused skin damage.
James Q. Del Rosso, DO, and Neal Bhatia, MD, discuss the role of topical and oral JAK inhibitors in inflammatory disease management.
